Inflammatory cytokine pathways in keratinocytes

Keratinocytes are the primary cells of the epidermis and play a central role in the skin's immune response by acting as both targets and sources of inflammatory cytokines (PubMed: 30107238). In chronic inflammatory skin diseases such as psoriasis and atopic dermatitis, these cells are stimulated by cytokines like IL-17, IL-22, and TNF-α, which activate downstream signaling pathways including JAK/STAT and NF-κB (Nature Reviews Immunology, 2020). This activation results in a feed-forward loop where keratinocytes produce chemokines (e.g., CXCL8, CCL20) and antimicrobial peptides that further recruit and activate immune cells (Journal of Investigative Dermatology, 2019). Therapeutic intervention typically involves monoclonal antibodies that neutralize specific cytokines or small molecules that inhibit the intracellular kinases responsible for signal transduction (StatPearls, 2023). By disrupting these pathways, drugs can restore normal skin barrier function and reduce the clinical symptoms of chronic inflammatory skin diseases (NIH: PMC6541658). Common targets within these pathways include the IL-17 receptor, the IL-4 receptor, and various Janus kinases (JAK1, JAK2, JAK3, and TYK2) (PubMed: 31041429). Modulation of these pathways has revolutionized the treatment of moderate-to-severe inflammatory dermatoses, though it requires careful monitoring for immunosuppression-related side effects (Journal of the American Academy of Dermatology, 2022).

Other names

Keratinocyte inflammatory signalingEpidermal cytokine pathwaysCytokine-mediated keratinocyte activation (PubMed: 30107238)Keratinocyte-immune axis (Nature Reviews Immunology, 2020)

The mechanism of action involves the pharmacological modulation of specific components within the keratinocyte inflammatory network. This is achieved by neutralizing pro-inflammatory cytokine ligands such as IL-17A and TNF-α, blocking their respective cell-surface receptors like IL-17RA and IL-4Rα, or inhibiting intracellular signaling enzymes such as Janus kinases (JAK1, JAK2, JAK3, and TYK2) to prevent the transcription of genes involved in epidermal hyperplasia and inflammation (PubMed: 31041429, StatPearls: NBK541061).